The evolutionary impact of androgen levels on prostate cancer in a multi-scale mathematical model

Biology Direct

Volumn 5, Issue , 2010, Pages

  Eikenberry, Steffen E ^a,b   Nagy, John D ^c   Kuang, Yang ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c Scottsdale Community College   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; TESTOSTERONE;

ANIMAL; ARTICLE; DRUG EFFECT; GENE EXPRESSION REGULATION; HUMAN; MALE; METABOLISM; PATHOLOGY; PROSTATE TUMOR; THEORETICAL MODEL;

ANDROGENS; ANIMALS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MODELS, THEORETICAL; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TESTOSTERONE;

EID: 77950931652     PISSN: None     EISSN: 17456150     Source Type: Journal    
DOI: 10.1186/1745-6150-5-24     Document Type: Article

References (99)

1. Dobzhansky T. Nothing in biology makes sense except in the light of evolution. Am Biol Teacher 1973, 35:125-129.
2. Law LW. Origin of the resistance of leukaemic cells to folic acid antagonists. Nature 1952, 169:628-629. 10.1038/169628a0, 14929259.
3. Nowell PC. The clonal evolution of tumor cell populations. Science 1976, 194:23-28. 10.1126/science.959840, 959840.
4. Williams GC, Ness RM. The dawn of Darwinian medicine. Q Rev Biol 1991, 66:1-22. 10.1086/417048, 2052670.
5. Greaves M. Cancer: the evolutionary legacy. 2000, Oxford University Press, Oxford.
6. Greaves M. Darwinian medicine: a case for cancer. Nat Rev Cancer 2007, 7:213-221. 10.1038/nrc2071, 17301845.
7. Leroi AM, Koufopanou V, Burt A. Cancer selection. Nat Rev Cancer 2003, 3:226-231. 10.1038/nrc1016, 12612657.
8. Nagy JD. The ecology and evolutionary biology of cancer: a review of mathematical models of necrosis and tumor cell diversity. Math Biosci Eng 2005, 2:381-418.
9. Crespi B, Summers K. Evolutionary biology of cancer. Trends Ecol Evol 2005, 20:545-552. 10.1016/j.tree.2005.07.007, 16701433.
10. Merlo LMF, Pepper JW, Reid BJ, Maley CC. Cancer as an evolutionary and ecological process. Nat Rev Cancer 2006, 6:924-935. 10.1038/nrc2013, 17109012.
11. Maley CC, Reid BJ. Natural selection in neoplastic progression of Barret's esophagus. Semin Cancer Biol 2005, 15:474-483. 10.1016/j.semcancer.2005.06.004, 16043360.
12. Gatenby RA, Gawlinski ET. The glycolytic phenotype in carcinogenesis and tumor invasion: insights through mathematical models. Cancer Res 2003, 63:3847-3854.
13. Gatenby RA, Gillies RJ. Why do cancers have high aeorbic glycolysis?. Nat Rev Cancer 2004, 4:891-899. 10.1038/nrc1478, 15516961.
14. Patel AA, Gawlinski ET, Lemieux SK, Gatenby RA. A cellular automaton model of early tumor growth and invasion: the effects of native tissue vascularity and increased anaerobic tumor metabolism. J Theor Biol 2001, 213:315-331. 10.1006/jtbi.2001.2385, 11735284.
15. Maley CC, Forrest S. Exploring the relationship between neutral and selective mutations in cancer. Artif Life 2000, 6:325-345. 10.1162/106454600300103665, 11348585.
16. Maley CC, Reid BJ, Forrest S. Cancer prevention strategies that address the evolutionary dynamics of neoplastic cells: simulating benign cell boosters and selection for chemosensitivity. Cancer Epidemiol Biomarkers Prev 2004, 13:1375-1384.
17. Maley CC, Galipeau PC, Finley JC, Wongsurawat VJ, Li X, Sanchez CA, Paulson TG, Blount PL, Risques R-A, Rabinovitch PS, Reid BJ. Genetic clonal diverstiy predicts progression to esophageal adenocarcinoma. Nat Genet 2006, 38:468-473. 10.1038/ng1768, 16565718.
18. Nagy JD. Competition and natural selection in a mathematical model of cancer. Bull Math Biol 2004, 66:663-687. 10.1016/j.bulm.2003.10.001, 15210312.
19. Nagy JD, Victor EM, Cropper JH. Why don't all whales have cancer? A novel hypothesis resolving Peto's paradox. Int Comp Biol 2007, 47:317-328.
20. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer Statistics, 2008. CA Cancer J Clin 2008, 58:71-96. 10.3322/CA.2007.0010, 18287387.
21. Stacewicz-Sapuntzakis M, Borthakur G, Burns JL, Bowen PE. Correlations of dietary patterns with prostate health. Mol Nutr Food Res 2008, 52:114-130. 10.1002/mnfr.200600296, 18080240.
22. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004, 25:276-308. 10.1210/er.2002-0032, 15082523.
23. Wright AS, Douglas RC, Thomas LN, Lazier CB, Rittmaster RS. Androgen-induced regrowth in the castrated rat ventral prostate: role of 5α-reductase. Endocrinology 1999, 140:4509-15. 10.1210/en.140.10.4509, 10499505.
24. Koivisto P, Kolmer M, Visakorpi T, Kallioniemi OP. Androgen receptor gene and hormonal therapy failure of prostate cancer. Am J Pathol 1998, 152:1-9. 1858130, 9422516.
25. Rittmaster RS, Manning AP, Wright AS, Thomas LN, Whitefield S, Norman RW, Lazier CB, Rowden G. Evidence for atrophy and apoptosis in the ventral prostate of rats given the 5 alpha-reductase inhibitor finasteride. Endocrinology 1995, 136:741-8. 10.1210/en.136.2.741, 7835306.
26. Prehn RT. On the Prevention and Therapy of Prostate Cancer by Androgen Administration. Cancer Res 1999, 59:4161-64.
27. Banerjee PP, Banerjee S, Brown TR. Increased androgen receptor expression correlates with development of age-dependent, lobe-specific spontaneous hyperplasia of the brown Norway rat prostate. Endocrinology 2001, 142:4066-75. 10.1210/en.142.9.4066, 11517186.
28. Marks LS, Partin AW, Dorey FJ, Gormley GJ, Epstein JI, Garris JB, Macairan ML, Shery ED, Santos PB, Stoner E, deKernion JB. Long-term effects of finasteride on prostate tissue composition. Urology 1999, 53:574-80. 10.1016/S0090-4295(98)00567-6, 10096387.
29. Prostate Cancer Trialists' Collaborative Group Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000, 355:1491-8. 10.1016/S0140-6736(00)02163-2, 10801170, Prostate Cancer Trialists' Collaborative Group.
30. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004, 10:33-9. 10.1038/nm972, 14702632.
31. Rocchi P, Muracciole X, Fina F, Mulholland DJ, Karsenty G, Palmari J, Ouafik L, Bladou F, Martin PM. Molecular analysis integrating different pathways associated with androgen-independent progression in LuCaP 23.1 xenograft. Oncogene 2004, 23:9111-9. 10.1038/sj.onc.1208154, 15489889.
32. Krajewska M, Krajewski S, Epstein JI, Shabaik A, Sauvageot J, Song K, Kitada S, Reed JC. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 1996, 148:1567-76. 1861561, 8623925.
33. Story MT. Regulation of prostate growth by fibroblast growth factors. World J Urol 1995, 13:297-305. 10.1007/BF00185973, 8581001.
34. Rittmaster RS, Norman RW, Thomas LN, Rowden G. Evidence for atrophy and apoptosis in the prostates of men given finasteride. J Clin Endocrinol Metab 1996, 81:814-9. 10.1210/jc.81.2.814, 8636309.
35. Raynaud JP. Prostate cancer risk in testosterone-treated men. J Steroid Biochem Mol Biol 2006, 102:261-6. 10.1016/j.jsbmb.2006.09.032, 17113983.
36. Sofikerim M, Eskicorapci S, Oruç O, Ozen H. Hormonal predictors of prostate cancer. Urol Int 2007, 79:13-8. 10.1159/000102906, 17627161.
37. Schatzl G, Madersbacher S, Thurridl T, Waldmüller J, Kramer G, Haitel A, Marberger M. High-grade prostate cancer is associated with low serum testosterone levels. Prostate 2001, 47:52-8. 10.1002/pros.1046, 11304729.
38. Stattin P, Lumme S, Tenkanen L, Alfthan H, Jellum E, Hallmans G, Thoresen S, Hakulinen T, Luostarinen T, Lehtinen M, Dillner J, Stenman UH, Hakama M. High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study. Int J Cancer 2004, 108:418-24. 10.1002/ijc.11572, 14648709.
39. Severi G, Morris HA, MacInnis RJ, English DR, Tilley W, Hopper JL, Boyle P, Giles GG. Circulating steroid hormones and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006, 15:86-91. 10.1158/1055-9965.EPI-05-0633, 16434592.
40. Iversen P, Rasmussen F, Christensen IJ. Serum testosterone as a prognostic factor in patients with advanced prostatic carcinoma. Scand J Urol Nephrol Suppl 1994, 157:41-7.
41. Eriksson A, Carlström K. Prognostic value of serum hormone concentrations in prostatic cancer. Prostate 1988, 13:249-56. 10.1002/pros.2990130307, 3211806.
42. Matzkin H, Perito PE, Soloway MS. Prognostic factors in metastatic prostate cancer. Cancer 1993, 72:3788-92. 10.1002/1097-0142(19931215)72:12+<3788::AID-CNCR2820721705>3.0.CO;2-J , 7504577.
43. Adlercreutz H, Rannikko S, Kairento AL, Karonen SL. Hormonal pattern in prostatic cancer. II. Correlation with primary response to endocrine treatment. Acta Endocrinol (Copenh) 1981, 98:634-40.
44. Hickey D, Todd B, Soloway MS. Pre-treatment testosterone levels: significance in androgen deprivation therapy. J Urol 1986, 136:1038-40.
45. Harper ME, Pierrepoint CG, Griffiths K. Carcinoma of the prostate: relationship of pretreatment hormone levels to survival. Eur J Cancer Clin Oncol 1984, 20:477-82. 10.1016/0277-5379(84)90232-3, 6426967.
46. Soloway MS, Ishikawa S, Zwaag R, Todd B. Prognostic factors in patients with advanced prostate cancer. Urology 1989, 33:53-6. 10.1016/0090-4295(89)90107-6, 2775378.
47. Ishikawa S, Soloway MS, Zwaag R, Todd B. Prognostic factors in survival free of progression after androgen deprivation therapy for treatment of prostate cancer. J Urol 1989, 141:1139-42.
48. Chodak GW, Vogelzang NJ, Caplan RJ, Soloway M, Smith JA. Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex Study Group. JAMA 1991, 265:618-21. 10.1001/jama.265.5.618, 1824790.
49. Daniell HW. A worse prognosis for men with testicular atrophy at therapeutic orchiectomy for prostate carcinoma. Cancer 1998, 83:1170-3. 10.1002/(SICI)1097-0142(19980915)83:6<1170::AID-CNCR16>3.0.CO;2-2, 9740082.
50. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003, 349:215-24. 10.1056/NEJMoa030660, 12824459.
51. Lucia MS, Epstein JI, Goodman PJ, Darke AK, Reuter VE, Civantos F, Tangen CM, Parnes HL, Lippman SM, La Rosa FG, Kattan MW, Crawford ED, Ford LG, Coltman CA, Thompson IM. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007, 99:1375-83. 10.1093/jnci/djm117, 17848673.
52. Briganti A, Chun FK, Suardi N, Gallina A, Walz J, Graefen M, Shariat S, Ebersdobler A, Rigatti P, Perrotte P, Saad F, Montorsi F, Huland H, Karakiewicz PI. Prostate volume and adverse prostate cancer features: fact not artifact. Eur J Cancer 2007, 43:2669-77. 10.1016/j.ejca.2007.09.022, 17996442.
53. Freedland SJ, Isaacs WB, Platz EA, Terris MK, Aronson WJ, Amling CL, Presti JC, Kane CJ. Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study. J Clin Oncol 2005, 23:7546-54.
54. Wilt TJ, MacDonald R, Hagerty K, Schellhammer P, Kramer BS. Five-alpha-reductase Inhibitors for prostate cancer prevention. Cochrane Database Syst Rev 2008, 2:CD007091.
55. Kramer BS, Hagerty KL, Justman S, Somerfield MR, Albertsen PC, Blot WJ, Carter HB, Costantino JP, Epstein JI, Godley PA, Harris RP, Wilt TJ, Wittes J, Zon R, Schellhammer P. Use of 5alpha-reductase inhibitors for prostate cancer chemoprevention: american society of clinical oncology/american urological association 2008 clinical practice guideline. J Urol 2009, 181:1642-57. 10.1016/j.juro.2009.01.071, 19249063.
56. Jackson TL. A mathematical model of prostate tumor growth and androgen-independent relapse. Discrete and Continuous Dynamical Systems-Series B 2004, 4:187-201.
57. Jackson TL. A mathematical investigation of the multiple pathways to recurrent prostate cancer: comparison with experimental data. Neoplasia 2004, 6:697-704. 10.1593/neo.04259, 1531673, 15720795.
58. Ideta A, Tanaka G, Takeuchi T, Aihara K. A Mathematical Model of Intermittent Androgen Suppression for Prostate Cancer. J Nonlinear Sci 2008, 18:593-614.
59. Potter LK, Zager MG, Barton HA. Mathematical model for the androgenic regulation of the prostate in intact and castrated adult male rats. Am J Physiol Endocrinol Metab 2006, 291:E952-64. 10.1152/ajpendo.00545.2005, 16757547.
60. Wright AS, Thomas LN, Douglas RC, Lazier CB, Rittmaster RS. Relative potency of testosterone and dihydrotestosterone in preventing atrophy and apoptosis in the prostate of the castrated rat. J Clin Invest 1996, 98:2558-63. 10.1172/JCI119074, 507713, 8958218.
61. Wang Z, Tufts R, Haleem R, Cai X. Genes regulated by androgen in the rat ventral prostate. Proc Natl Acad Sci USA 1997, 94:12999-3004. 10.1073/pnas.94.24.12999, 24252, 9371789.
62. Jiang F, Wang Z. Identification of Androgen-Responsive Genes in the Rat Ventral Prostate by Complementary Deoxyribonucleic Acid Subtraction and Microarray. Endocrinology 2003, 144:1257-1265. 10.1210/en.2002-220718, 12639908.
63. Van Doorn E, Craven S, Bruchovsky N. The relationship between adrogen receptors and the hormonally controlled responses of rat ventral prostate. Biochem J 1976, 160:11-21. 1164195, 1008839.
64. McKeehan WL, Adams PS, Rosser MP. Direct mitogenic effects of insulin, epidermal growth factor, glucocorticoid, cholera toxin, unknown pituitary factors and possibly prolactin, but not androgen, on normal rat prostate epithelial cells in serum-free, primary cell culture. Cancer Res 1984, 44:1998-2010.
65. Cronauer MV, Nessler-Menardi C, Klocker H, Maly K, Hobisch A, Bartsch G, Culig Z. Androgen receptor protein is down-regulated by basic fibroblast growth factor in prostate cancer cells. Br J Cancer 2000, 82:39-45. 10.1054/bjoc.1999.0874, 2363213, 10638964.
66. Banerjee PP, Banerjee S, Lai JM, Strandberg JD, Zirkin BR, Brown TR. Age-dependent and lobe-specific spontaneous hyperplasia in the brown Norway rat prostate. Biol Reprod 1998, 59:1163-70. 10.1095/biolreprod59.5.1163, 9780323.
67. Banerjee PP, Banerjee S, Dorsey R, Zirkin BR, Brown TR. Age- and lobe-specific responses of the brown Norway rat prostate to androgen. Biol Reprod 1994, 51:675-84. 10.1095/biolreprod51.4.675, 7819449.
68. Saran M, Bors W. Radical reactions in vivo - an overview. Radiat Environ Biophys 1990, 29:249-262. 10.1007/BF01210406, 2281132.
69. Tam NN, Gao Y, Leung YK, Ho SM. Androgenic regulation of oxidative stress in the rat prostate: involvement of NAD(P)H oxidases and antioxidant defense machinery during prostatic involution and regrowth. Am J Pathol 2003, 163:2513-22. 1892368, 14633623.
70. Cayatte C, Pons C, Guigonis JM, Pizzol J, Elies L, Kennel P, Rouquié D, Bars R, Rossi B, Samson M. Protein profiling of rat ventral prostate following chronic finasteride administration: identification and localization of a novel putative androgen-regulated protein. Mol Cell Proteomics 2006, 5:2031-43. 10.1074/mcp.M600165-MCP200, 16837577.
71. Pang ST, Dillner K, Wu X, Pousette A, Norstedt G, Flores-Morales A. Gene expression profiling of androgen deficiency predicts a pathway of prostate apoptosis that involves genes related to oxidative stress. Endocrinology 2002, 143:4897-4906. 10.1210/en.2002-220327, 12446617.
72. Shabsigh A, Ghafar MA, de la Taille A, Burchardt M, Kaplan SA, Anastasiadis AG, Buttyan R. Biomarker analysis demonstrates a hypoxic environment in the castrated rat ventral prostate gland. J Cell Biochem 2001, 81:437-44. 10.1002/1097-4644(20010601)81:3<437::AID-JCB1057>3.0.CO;2-6, 11255226.
73. Simon MC. Mitochondrial reactive oxygen species are required for hypoxic HIF alpha stabilization. Adv Exp Med Biol 2006, 588:165-70. full_text, 17089888.
74. Tam NN, Leav I, Ho SM. Sex hormones induce direct epithelial and inflammation-mediated oxidative/nitrosative stress that favors prostatic carcinogenesis in the noble rat. Am J Pathol 2007, 171:1334-41. 10.2353/ajpath.2007.070199, 1988882, 17717140.
75. Ripple MO, Henry WF, Rago RP, Wilding G. Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells. J Natl Cancer Inst 1997, 89:40-8. 10.1093/jnci/89.1.40, 8978405.
76. Davies KJ. The broad spectrum of responses to oxidants in proliferating cells: a new paradigm for oxidative stress. IUBMB Life 1999, 48:41-7.
77. Scheffer M, Hosper SH, Meijer ML, Moss B, Jeppesen E. Alternative Equilibria in Shallow Lakes. Trends in Ecology & Evolution 1993, 8:275-79.
78. Banerjee S, Banerjee PP, Brown TR. Castration-induced apoptotic cell death in the Brown Norway rat prostate decreases as a function of age. Endocrinology 2000, 141:821-32. 10.1210/en.141.2.821, 10650965.
79. Martel C, Trudel C, Couet J, Labrie C, Bélanger A, Labrie F. Blockade of androstenedione-induced stimulation of androgen-sensitive parameters in the rat prostate by combination of Flutamide and 4-MA. Mol Cell Endocrinol 1993, 91:43-9. 10.1016/0303-7207(93)90253-G, 8472853.
80. Wilson EM, French FS. Binding properties of androgen receptors. Evidence for identical receptors in rat testis, epididymis, and prostate. J Biol Chem 1976, 51:5620-9.
81. Lea OA, French FS. Androgen receptor protein in the androgen-dependent Dunning R-3327 prostate carcinoma. Cancer Res 1981, 41:619-23.
82. Gregory CW, Johnson RT, Mohler JL, French FS, Wilson EM. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 2001, 61:2892-8.
83. Tilley WD, Marcelli M, Wilson JD, McPhaul MJ. Characterization and expression of a cDNA encoding the human androgen receptor. Proc Natl Acad Sci USA 1989, 86:327-31. 10.1073/pnas.86.1.327, 286457, 2911578.
84. Ellis RJ. Macromolecular crowding: obvious but underappreciated. Trends Biochem Sci 2001, 26:597-604. 10.1016/S0968-0004(01)01938-7, 11590012.
85. Quarmby VE, Yarbrough WG, Lubahn DB, French FS, Wilson EM. Autologous down-regulation of androgen receptor messenger ribonucleic acid. Mol Endocrinol 1990, 4:22-8. 10.1210/mend-4-1-22, 2325667.
86. Shan LX, Rodriguez MC, Janne OA. Regulation of androgen receptor protein and mRNA concentrations by androgens in rat ventral prostate and seminal vesicles and in human hepatoma cells. Mol Endocrinol 1990, 4:1636-46. 10.1210/mend-4-11-1636, 2177837.
87. Mora GR, Prins GS, Mahesh VB. Autoregulation of androgen receptor protein and messenger RNA in rat ventral prostate is protein synthesis dependent. J Steroid Biochem Mol Biol 1996, 58:539-49. 10.1016/0960-0760(96)00079-9, 8918980.
88. Prins GS, Woodham C. Autologous regulation of androgen receptor messenger ribonucleic acid in the separate lobes of the rat prostate gland. Biol Reprod 1995, 53:609-19. 10.1095/biolreprod53.3.609, 7578685.
89. Steinsapir J, Evans AC, Bryhan M, Muldoon TG. Androgen receptor dynamics in the rat ventral prostate. Biochim Biophys Acta 1985, 842:1-11.
90. Labrie F, Veilleux R. A wide range of sensitivities to androgens develops in cloned Shionogi mouse mammary tumor cells. Prostate 1986, 8:293-300. 10.1002/pros.2990080309, 3703748.
91. Labrie F, Veilleux R, Fournier A. Low androgen levels induce the development of androgen-hypersensitive cell clones in Shionogi mouse mammary carcinoma cells in culture. J Natl Cancer Inst 1988, 80:1138-47. 10.1093/jnci/80.14.1138, 3411627.
92. Imamoto T, Suzuki H, Akakura K, Komiya A, Nakamachi H, Ichikawa T, Igarashi T, Ito H. Pretreatment serum level of testosterone as a prognostic factor in Japanese men with hormonally treated stage D2 prostate cancer. Endocr J 2001, 48:573-8. 10.1507/endocrj.48.573, 11789562.
93. Massengill JC, Sun L, Moul JW, Wu H, McLeod DG, Amling C, Lance R, Foley J, Sexton W, Kusuda L, Chung A, Soderdahl D, Donahue T. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol 2003, 169:1670-5. 10.1097/01.ju.0000062674.43964.d0, 12686805.
94. Imamoto T, Suzuki H, Fukasawa S, Shimbo M, Inahara M, Komiya A, Ueda T, Shiraishi T, Ichikawa T. Pretreatment serum testosterone level as a predictive factor of pathological stage in localized prostate cancer patients treated with radical prostatectomy. Eur Urol 2005, 47:308-12. 10.1016/j.eururo.2004.11.003, 15716191.
95. Isom-Batz G, Bianco FJ, Kattan MW, Mulhall JP, Lilja H, Eastham JA. Testosterone as a predictor of pathological stage in clinically localized prostate cancer. J Urol 2005, 173:1935-7. 10.1097/01.ju.0000158040.33531.e7, 1855287, 15879785.
96. Nishiyama T, Ikarashi T, Hashimoto Y, Suzuki K, Takahashi K. Association between the dihydrotestosterone level in the prostate and prostate cancer aggressiveness using the Gleason score. J Urol 2006, 176:1387-91. 10.1016/j.juro.2006.06.066, 16952639.
97. Normington K, Russell DW. Tissue distribution and kinetic characteristics of rat steroid 5 alpha-reductase isozymes. Evidence for distinct physiological functions. J Biol Chem 1992, 267:19548-54.
98. van Royen ME, Cunha SM, Brink MC, Mattern KA, Nigg AL, Dubbink HJ, Verschure PJ, Trapman J, Houtsmuller AB. Compartmentalization of androgen receptor protein-protein interactions in living cells. J Cell Biol 2007, 177:63-72. 10.1083/jcb.200609178, 2064112, 17420290.
99. Farla P, Hersmus R, Trapman J, Houtsmuller AB. Antiandrogens prevent stable DNA-binding of the androgen receptor. J Cell Sci 2005, 118:4187-98. 10.1242/jcs.02546, 16141232.